A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations.
Publication Title
Clinical cancer research : an official journal of the American Association for Cancer Research
Document Type
Article
Publication Date
12-15-2017
Keywords
Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Genes, erbB-1; Humans; Male; Midazolam; Middle Aged; Mutation; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines
Clinical Institute
Cancer
Specialty
Oncology
COinS
